Core Viewpoint - Deutsche Bank upgraded Teladoc Health to Buy from Hold with a price target of $11, citing attractive valuation and a credible turnaround strategy for the BetterHelp segment [1] Group 1: Valuation and Market Position - Teladoc shares are currently trading at approximately 4.2 times Deutsche Bank's 2026 EBITDA estimate, one of the lowest multiples in the firm's coverage universe [2] - Such low valuations are typically associated with companies facing existential risks, which Deutsche Bank believes does not apply to Teladoc's expanding Integrated Care segment [2] Group 2: BetterHelp Segment Strategy - The BetterHelp business has been experiencing declines, but management has introduced a strategy to stabilize and grow the segment by shifting from a cash-pay model to insurance-covered therapy services [3] - Demand for insured therapy services is increasing, as evidenced by Universal Health Services' recent acquisition of Talkspace, a competitor in the insured therapy market [4] Group 3: Potential for Value Unlocking - The acquisition of Talkspace suggests a potential upside for Teladoc's current share price, indicating a path for unlocking value in the market [4]